Pathwork Dx Inks Deal with Kindstar to Offer Tissue of Origin Test in China | GenomeWeb

NEW YORK (GenomeWeb News) – Pathwork Diagnostics today announced a deal to offer its Pathwork Tissue of Origin Test for cancer diagnosis in China.

The deal with Kindstar Global, which claims to be the largest esoteric diagnostic testing business in China, expands the Redwood City, Calif.-based company's international network of test and service providers, Pathwork said. The agreement is the first international in vitro diagnostic deal for the company, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.